Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) EBITDA (2023 - 2025)

Xenetic Biosciences' EBITDA history spans 7 years, with the latest figure at -$623027.0 for Q4 2025.

  • For Q4 2025, EBITDA rose 43.32% year-over-year to -$623027.0; the TTM value through Dec 2025 reached -$2.8 million, up 32.58%, while the annual FY2025 figure was -$2.8 million, 32.58% up from the prior year.
  • EBITDA reached -$623027.0 in Q4 2025 per XBIO's latest filing, down from -$544734.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$499473.0 in Q3 2024 to a low of -$1.3 million in Q2 2024.
  • Average EBITDA over 3 years is -$962893.8, with a median of -$1.0 million recorded in 2024.
  • The largest YoY upside for EBITDA was 56.44% in 2024 against a maximum downside of 38.6% in 2024.
  • A 3-year view of EBITDA shows it stood at -$1.3 million in 2023, then increased by 12.47% to -$1.1 million in 2024, then skyrocketed by 43.32% to -$623027.0 in 2025.
  • Per Business Quant, the three most recent readings for XBIO's EBITDA are -$623027.0 (Q4 2025), -$544734.0 (Q3 2025), and -$724412.0 (Q2 2025).